The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.
The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.
The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.
The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.
The identification of the subtypes allows future studies to target homogeneous subtype samples, resolve inconsistencies, personalize treatment and utilize preventive interventions.
Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.
The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.
Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.
The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.
